TNGX Latest Press Releases

-- October 23, 2026 --

Tango Presents Promising Results from Phase 1/2 Study of Vopimetostat and Daraxonrasib in Pancreatic Cancer and Provides Updates to Development Strategy Globe Newswire 6:30 AM

-- October 16, 2026 --

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026 Globe Newswire 7:00 AM

-- September 3, 2026 --

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 1, 2026 --

Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference Globe Newswire 7:00 AM

-- August 11, 2026 --

NeOnc Approaches a Major Biotech Inflection Point as tomorrow's Brain-Cancer Data is set to Collide with a Tight Float Globe Newswire 11:00 AM

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights Globe Newswire 7:00 AM

-- August 6, 2026 --

Tango Therapeutics Announces Executive Chair Transition Globe Newswire 6:24 PM

-- June 22, 2026 --

Tango Therapeutics Appoints Robert Azelby to Board of Directors Globe Newswire 4:05 PM

-- June 9, 2026 --

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering Globe Newswire 10:49 PM

-- June 8, 2026 --

Tango Therapeutics Announces Proposed $500 Million Public Offering Globe Newswire 4:01 PM

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer Globe Newswire 6:59 AM

-- June 5, 2026 --

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes